Celadon Pharmaceuticals plc (CEL) ORD GBP0.01

Celadon Pharmaceuticals Plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. The Company is focused on growing indoor hydroponic cannabis initially for the chronic pain market. The Company's facility comprises indoor hydroponic cultivation, proprietary GMP extraction and manufacturing and an analytical and R&D laboratory. It also has a minority interest in early-stage biopharma Kingdom therapeutics. The Company’s products include CEL-F15/0, CEL-F20/0, CEL-F19/0, and Cannabis Oil API. CEL-F15/0 is a meticulously bred cannabis strain deriving from RX11 genetics. CEL-F20/0 is a meticulously bred cannabis strain deriving from Zerberry genetics.